Vimarsana
Biggest News Aggregation in the World

Page 13 - Commodore Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Commodore Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Commodore Capital Today - Breaking & Trending Today

Immunovant, Inc. (NASDAQ:IMVT) Insider William L. Macias Sells 426 Shares - Vimarsana News

Immunovant, Inc. (NASDAQ:IMVT) Insider William L. Macias Sells 426 Shares

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider William L. Macias sold 426 shares of Immunovant stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $24.94, for a total value of $10,624.44. Following the completion of the transaction, the insider now directly owns 349,725 shares of the […]

Research Analysts Offer Predictions for Xenon Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:XENE) - Vimarsana News

Research Analysts Offer Predictions for Xenon Pharmaceuticals Inc.'s FY2024 Earnings (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Xenon Pharmaceuticals in a research note issued on Tuesday, July 11th. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will post earnings per share of ($2.42) for the year. Cantor Fitzgerald currently has […]

Around $8.5M Bet On Eagle Bulk Shipping? Check Out These 4 Stocks Insiders Are Buying - Asana (NYSE:ASAN), Eagle Bulk Shipping (NYSE:EGLE) - Vimarsana News

Around $8.5M Bet On Eagle Bulk Shipping? Check Out These 4 Stocks Insiders Are Buying - Asana (NYSE:ASAN), Eagle Bulk Shipping (NYSE:EGLE)

Although US stocks closed mostly higher on Thursday, there were a few notable insider trades.

Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs - Vimarsana News

Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs

/PRNewswire/ -- Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer across the U.S. and other...

Brokerages Set Allakos Inc. (NASDAQ:ALLK) Price Target at $13.60 - Vimarsana News

Brokerages Set Allakos Inc. (NASDAQ:ALLK) Price Target at $13.60

Shares of Allakos Inc. (NASDAQ:ALLK – Get Rating) have earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the […]

Source: wkrb13.com